OncoMatch/Clinical Trials/NCT06800391
Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients
Is NCT06800391 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day for pseudomyxoma peritonei.
Treatment: Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day — The goal of this clinical trial is to evaluate the safety and efficacy of neoadjuvant capecitabine and cyclophosphamide treatment in patients affected by huge Pseudomyxoma peritonei (PMP) (peritoneal cancer index \>28). Treatment consists of metronomic (low-dose medication for a prolonged time) of capecitabine plus cyclophosphamide for 6 months followed by standard of care cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The main question the trial aims to answer is which is the proportion of patients with complete cytoreduction at CRS/HIPEC after neoadjuvant metronomic approach with oral capecitabine and cyclophosphamide in patients affected by huge PMP.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Biomarker criteria
Excluded: DPYD deficiency
DPD deficiency
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic chemotherapy
Previous systemic chemotherapy
Cannot have received: biological therapy
Previous...biological therapy
Lab requirements
Blood counts
wbc count >3.0x109/l, absolute neutrophyl count >1.5x109/l, platelet count >100x109/l, and hemoglobin >10 g/dl
Kidney function
creatinine clearance >50 ml/min or serum creatinine <1.5 x unl
Liver function
bilirubin < 1.5 times the uln, alkaline phosphatase, aspartate transaminase, and alanine transaminase < 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06800391 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with DPYD alterations eligible?
No. DPYD deficiency is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 76 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify